Aristospan

(Triamcinolone hexacetonide)

ApprovedSmall molecule

EEthypharm

Aristospan is one of 112 small molecule programs targeting Radiculopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

111

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

RadiculopathyActive, not recruiting

Frozen ShoulderActive, not recruiting

KeloidActive, not recruiting

OsteoarthritisActive, not recruiting

ArthritisRecruiting

RadiculopathyPreclinical

Active, not recruiting

Frozen ShoulderPreclinical

Active, not recruiting

KeloidPreclinical

Active, not recruiting

OsteoarthritisApproved

Active, not recruiting

ArthritisApproved

Recruiting

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Aristospan

EEthypharm

Approved

5 2

Toradol

Roche

Preclinical

1 3

Bayer Aspirin

Enbrel

2 5

Glucophage

EMD Serono

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Infiltration

NCT05408065

Q1 2027

Post-ApprovalRecruiting

Arthritis

NCT06782529

Clinical

Trials by Indication[1]

Osteoarthritis5 trials

Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up

Completed·AAnika Therapeutics, Inc.·Phase 3·NCT03390036·526 enrolled

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

Completed·AAnika Therapeutics, Inc.·Phase 3·NCT04231318·231 enrolled

Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide

Completed·AAnika Therapeutics, Inc.·Phase 3·NCT03191903·576 enrolled

Show 2 more trials

Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.

Completed·FFederal University of São Paulo·Phase 4·NCT03086759·99 enrolled

Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis

Unknown status·FFederal University of São Paulo·Phase 4·NCT02829281·105 enrolled

Arthritis2 trials

Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis

Unknown status·UUppsala University·Phase 4·NCT02437461·159 enrolled

Knee Injections for Obese Patients With Knee Arthritis

Recruiting·MMayo Clinic·Phase 4·NCT06782529·40 enrolled

Infiltration1 trial

Comparison of the Analgesic Effect of 2 Shoulder Infiltrations

Recruiting·—·N/A·NCT05408065·84 enrolled

Pain Management1 trial

Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management

Completed·UUniversity of Florida·Phase 2·NCT01770912·24 enrolled

Frozen Shoulder1 trial

Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder

Completed·OOslo University Hospital·N/A·NCT00840229·122 enrolled

4 more indications

Radiculopathy1 trial

Epidural Clonidine for Lumbosacral Radiculopathy

Terminated·MMayo Clinic·N/A·NCT00588354·26 enrolled

Keloid1 trial

Photobiomodulation and the Intralesional Administration of Corticoid in the Keloid Surgery.

Completed·UUniversity of Nove de Julho·N/A·NCT04824612·4 enrolled

Intraarticular1 trial

Effectiveness Intraarticular Corticosteroid

Unknown status·FFederal University of São Paulo·N/A·NCT01851278·60 enrolled

Gonarthrosis1 trial

Comparison of the Effectiveness of Ultrasound-Guided Perimeniscal Steroid and Dextrose Injections in Knee Osteoarthritis

Completed·KKastamonu University·Approved·NCT06308887·32 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ARISTOSPAN

NDA NDA016466

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Triamcinolone hexacetonide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triamcinolone hexacetonide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triamcinolone hexacetonide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA016466). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Ethypharm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEthypharm

Aristospan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Osteoarthritis5 trials

Arthritis2 trials

Infiltration1 trial

Pain Management1 trial

Frozen Shoulder1 trial

Radiculopathy1 trial

Keloid1 trial

Intraarticular1 trial

Gonarthrosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News